Craig Hendrix

Datos Biográficos

ID10729637
NOMBRECraig Hendrix
NOMBRESCraig
APELLIDOHendrix
FIRMAHENDRIX C
AFILIACIONESFrom the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.), the Lundquist Institute at Harbor–UCLA Medical Center, Torrance (E.D.), the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) — all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.
VERIFICADONo
TOTAL DE OBRAS7
TOTAL DE CITAS0
TOTAL COMO AUTOR7
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN2012
AÑO MÁS RECIENTE DE PUBLICACIÓN2025
ÍNDICE H0

  • Assessing the Acceptability of a Tenofovir-Based Rectal Microbicide Douche among Young Men who Have Sex with Men

    Open AccessJose Bauermeister, Willey Lin et al.ARTICLEAIDS and Behavior2025

    Young men who have sex with men (YMSM) remain disproportionately affected by HIV, yet adherence to daily oral pre-exposure prophylaxis (PrEP) remains suboptimal. Rectal microbicides formulated as douches offer a behaviorally congruent alternative by leveraging existing douching practices. This study assessed the acceptability of a tenofovir-based rectal microbicide douche among YMSM. Eight YMSM (M = 20.9 years; range 18-24 years) participated in …

  • Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

    Open AccessRaphael J Landovitz, Deborah Donnell et al.ARTICLENew England Journal of Medicine2021

    BACKGROUND: Safe and effective long-acting injectable agents for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options for preventing HIV infection. METHODS: We conducted a randomized, double-blind, double-dummy, noninferiority trial to compare long-acting injectable cabotegravir (CAB-LA, an integrase strand-transfer inhibitor [INSTI]) at a dose of 600 mg, given intramuscularly every 8 …

  • Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States

    Open AccessElizabeth Montgomery, Lisa Noguchi et al.ARTICLEAIDS and Behavior2017

  • Utility of Different Adherence Measures for PrEP

    Open AccessAndrew Abaasa, Craig W Hendrix et al.ARTICLEAIDS and Behavior2017

    Measuring PrEP adherence remains challenging. In 2009-2010, the International AIDS Vaccine Initiative randomized phase II trial participants to daily tenofovir disoproxil fumarate/emtricitabine or placebo in Uganda and Kenya. Adherence was measured by electronic monitoring (EM), self-report (SR), and drug concentrations in plasma and hair. Each adherence measure was categorised as low, moderate, or high and also considered continuously; the incre…

  • Optimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men

    Open AccessKenneth H Mayer, Steven A Safren et al.ARTICLEAIDS and Behavior2016

  • HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention

    Open AccessDeborah Donnell, Jared M Baeten et al.ARTICLEJAIDS Journal of Acquired Immune…2014

    BACKGROUND: Antiretroviral pre-exposure prophylaxis (PrEP) is a novel HIV prevention strategy for which adherence is a known determinant of efficacy. Blood concentrations of PrEP medications are one objective marker of adherence. METHODS: In a placebo-controlled PrEP efficacy trial of tenofovir disoproxil fumarate (TDF) and TDF with emtricitabine (FTC/TDF) among 4747 African women and men with an HIV-infected partner, we measured plasma tenofovir…

  • Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women

    Jared M Baeten, Deborah Donnell et al.ARTICLENew England Journal of Medicine2012

    BACKGROUND: Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV-1) infection in heterosexual populations. METHODS: We conducted a randomized trial of oral antiretroviral therapy for use as preexposure prophylaxis among HIV-1-serodiscordant heterosexual couples from Kenya and Uganda. The HIV-1-seronegative partner in each couple was randomly assigned to one of three study regimens-…